

Hypertrophic Cardiomyopathy (HCM)

Short Name	Full Title + Study Description	Type	Investigator	Contact
HCM II	HCM II: Hypertrophic Cardiomyopathy (HCM) Clinic Research Registry	Observational	Dr. David Fermin	Jenni Schuitema Jenni.schuitema@spectrumhealth.org 616.391.6660
	<i>This is a registry that collects health information about patients who have Hypertrophic Cardiomyopathy (HCM). The information will be used for future research in understanding the disease and how to manage it.</i>			
VALOR-HCM	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy	Drug	Dr. David Fermin	Katy Wachter Katy.Wachter@spectrumhealth.org 616.486.7481

The purpose of this study is to evaluate the effect of Mavacamten versus a placebo on reducing the number of septal reduction therapy (SRT) procedures performed in patients with symptomatic, obstructive hypertrophic cardiomyopathy (oHCM, also known as HOCM). SRT procedures include septal myectomy, a surgical, open heart procedure and ethanol ablation (also known as alcohol septal ablation) which is a type of cardiac catheterization.